These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 18992382

  • 1. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis.
    Rogoza RM, Ferko N, Bentley J, Meijer CJ, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL.
    Vaccine; 2008 Sep 15; 26 Suppl 5():F46-58. PubMed ID: 18992382
    [Abstract] [Full Text] [Related]

  • 2. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 4. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX.
    Vaccine; 2008 Aug 19; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [Abstract] [Full Text] [Related]

  • 5. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ.
    Vaccine; 2008 Jul 29; 26(32):4015-24. PubMed ID: 18602731
    [Abstract] [Full Text] [Related]

  • 6. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.
    Vaccine; 2009 Aug 13; 27(37):5111-9. PubMed ID: 19567242
    [Abstract] [Full Text] [Related]

  • 7. The current and future role of screening in the era of HPV vaccination.
    Myers E, Huh WK, Wright JD, Smith JS.
    Gynecol Oncol; 2008 May 13; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
    Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B.
    Vaccine; 2008 Sep 15; 26 Suppl 5():F29-45. PubMed ID: 18992380
    [Abstract] [Full Text] [Related]

  • 9. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.
    BJOG; 2012 Jan 15; 119(2):177-86. PubMed ID: 21794070
    [Abstract] [Full Text] [Related]

  • 10. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.
    Vaccine; 2009 Oct 19; 27(44):6196-202. PubMed ID: 19698807
    [Abstract] [Full Text] [Related]

  • 11. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
    Heideman DA, Snijders PJ, Berkhof J, Verheijen RH, Helmerhorst TJ, Meijer CJ.
    BJOG; 2008 Jul 19; 115(8):938-46. PubMed ID: 18651878
    [Abstract] [Full Text] [Related]

  • 12. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Jul 19; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J.
    Vaccine; 2007 Sep 17; 25(37-38):6677-91. PubMed ID: 17706844
    [Abstract] [Full Text] [Related]

  • 14. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.
    Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/242-9. PubMed ID: 16950013
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.
    Garnett GP, Kim JJ, French K, Goldie SJ.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/178-86. PubMed ID: 16950005
    [Abstract] [Full Text] [Related]

  • 18. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL, Coutlée F, Ferenczy A.
    Public Health Genomics; 2009 Aug 31; 12(5-6):352-61. PubMed ID: 19684447
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recommendations for cervical cancer prevention in Latin America and the Caribbean.
    Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, Bosch FX.
    Vaccine; 2008 Aug 19; 26 Suppl 11():L96-L107. PubMed ID: 18945407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.